Shopping Cart (0)
My Account

Shopping Cart
3 for 2 Offer SELECTBIO Conferences Innovations in Microfluidics 2024: Rapid Prototyping, 3D-PrintingLiquid Biopsy 2024: Technologies & ApplicationsCirculating Biomarkers and Extracellular Vesicles Europe 2024Point-of-Care, Biosensors and Rapid Dx Europe 2024Organoids and Spheroids Europe 2024ePoster Award Prize

Designing & Setting up Assays for RNAi Screening (siRNA, miRNA, & shRNA)



Held in conjunction with Academic Discovery Workshop

22 Sep 2014, at 1:00-5:00 in Baltimore, MA, USA

Price:



The course is designed to provide in-depth information on how to go about assay design and setting up RNAi screening experiments. The challenges working with siRNAs and shRNAs and the delivery reagents needed to get them into the appropriate cells and tissues will be discussed.

Who Should Attend:
Anyone interested in a functional genomics approach for screening (focused or genome-wide libraries)
Anyone interested in learning about best practices of RNAi screening from assay optimization to secondary assays
Anyone new to assay optimization or RNAi screening
Anyone interested in advances in high-throughput RNAi screening 

How You Will Benefit From This Course:
Individuals that are using or potentially plan on RNAi research in their work
Researchers who already have experience with RNAi and would like to expand their knowledge on current trends

Course Topics:
Introduction to the biology of RNAi
How to translate your biological question into a relevant assay
Choice of RNAi screens: siRNA versus shRNA, whole genome versus targeted, pools versus individuals
Discussion on currently available transfection agents, libraries and other reagents
Tackling assay development and optimization
High-throughput screening issues: automation and type of instrumentation
Choice of assay controls, quality control, and data visualization and analysis
Identifiying and controlling for off-target effects 
Validation and secondary assays



Chi Yun

Chi Yun, Director, NYU School Of Medicine


David Shum

David Shum, Assay Development Specialist, Memorial Sloan-Kettering Cancer Center


Scott Martin

Scott Martin, Group Leader, National Institutes of Health